CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00312-07v1
14/11/1416    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vauloup-Fellous, C.
Right arrow Articles by Grangeot-Keros, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vauloup-Fellous, C.
Right arrow Articles by Grangeot-Keros, L.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2007, p. 1416-1419, Vol. 14, No. 11
1071-412X/07/$08.00+0     doi:10.1128/CVI.00312-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Development of a Rapid and Convenient Method for Determination of Rubella Virus-Specific Immunoglobulin G Avidity{triangledown}

Christelle Vauloup-Fellous,1,2* Jessica Ursulet-Diser,2 and Liliane Grangeot-Keros1,2

Faculty of Medicine Paris-Sud, University Paris-Sud 11, Le Kremlin-Bicêtre F-94276, France,1 Department of Microbiology and Immunology, AP-HP, Antoine Béclère Hospital, Clamart F-92141, France2

Received 24 July 2007/ Returned for modification 6 September 2007/ Accepted 19 September 2007

We describe here a rapid and semiautomated method for the determination of rubella virus immunoglobulin G (IgG) avidity with the VIDAS instrument. A total of 153 serum samples from persons with naturally acquired rubella virus infections (n = 98), from vaccinated persons (n = 44), and from patients with autoantibodies (n = 11) were included in this study. The rubella virus-specific IgG avidity assay we developed for the VIDAS instrument was evaluated by comparison with an in-house method. Results obtained with the VIDAS instrument allow considering this method valuable to help confirm or exclude acute primary infection or recent vaccination.

* Corresponding author. Mailing address: Service de Microbiologie-Immunologie Biologique, Hôpital Antoine Béclère, 92141 Clamart Cedex, France. Phone: (33) 1 45 37 42 86. Fax: (33) 1 46 32 67 96. E-mail: christelle.vauloup{at}abc.aphp.fr

{triangledown} Published ahead of print on 3 October 2007.

Clinical and Vaccine Immunology, November 2007, p. 1416-1419, Vol. 14, No. 11
1071-412X/07/$08.00+0     doi:10.1128/CVI.00312-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.